Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation
NCT00372502 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine if there is equivalence between two different methods of treating patients with severe bloodstream infection called sepsis. We will randomly assign patients to one of two treatment methods. One of the treatment methods is the current standard of care and uses an infrared sensor on the end of a catheter to determine the adequacy of treatment. The second treatment method is identical to the first but instead of the infrared sensor a blood test that is performed as a part of standard care (with blood drawn from the catheter) will be used to determine the adequacy of treatment. This study will attempt to determine an easier method of guiding treatment.
Conditions Studied
Interventions
- PROCEDURE Modified EGDT
- PROCEDURE Standard EGDT
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center — Boston
New Jersey
- Cooper Hospital — Camden
North Carolina
- Carolinas Medical Center — Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00372502
The ClinicalTrials.gov registry entry for NCT00372502 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of General Medical Sciences (NIGMS), which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Septic Shock appearing as the primary indexed condition, and to 2 interventions — of which Modified EGDT is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00372502 reports 3 study locations spanning 3 distinct geographic areas — top geographies include Massachusetts, New Jersey, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00372502 about?
NCT00372502 is a clinical study titled "Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation". The purpose of this study is to determine if there is equivalence between two different methods of treating patients with severe bloodstream infection called sepsis. We will randomly assign patients to one of two treatment methods. One of the treatment methods is the current standard of care and use...
What is the current status of trial NCT00372502?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2007-01. Estimated completion is 2008-12.
What conditions does trial NCT00372502 study?
This clinical trial studies the following conditions: Septic Shock, Severe Sepsis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00372502?
The interventions under investigation include: Modified EGDT (PROCEDURE), Standard EGDT (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00372502?
This trial is sponsored by National Institute of General Medical Sciences (NIGMS), which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00372502 being conducted?
This trial has 3 study locations across Massachusetts, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.